RG7112 10 mg | Purity Not Available
TargetMol

RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor.
More Information Supplier PageRG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor.
More Information Supplier PageRG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor.
More Information Supplier PagePFI-3 is a selective chemical inhibitor for SMARCA (2/4) (Kd = 89 nM)and PBI (5) bromodomains which may result in the delay and prevention of breast cancer.
More Information Supplier PagePamapimod (R-1503, Ro4402257) is a novel, selective inhibitor of p38 mitogen-activated protein kinase. It inhibits p38α and p38β enzymatic activity with IC50 values of 0.014±0.002 and 0.48± 0.04 microM, respectively with no activity against p38delta or p38 gamma isoforms.
More Information Supplier PageNSC348884 is a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis, inhibits cell proliferation at an IC50 of 1.7-4.0 μM in distinct cancer cell lines.
More Information Supplier PageCPI-637 is a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor.
More Information Supplier PageBromodeoxyuridine (BrdU), a nucleoside analog, are used in the detection of proliferating cells and competes with thymidine for incorporation into DNA.
More Information Supplier PageAZD8186 is an effective and specific PI3Kβ/δ inhibitor (IC50: 4/12 nM).
More Information Supplier PageAZD8186 is an effective and specific PI3Kβ/δ inhibitor (IC50: 4/12 nM).
More Information Supplier PageZoledronate is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with […]
More Information Supplier Page